[Comparison study of visual function and patient satisfaction in patients with monovision and patients with bilateral multifocal intraocular lenses].

OBJECTIVE To compare visual function and patient satisfaction in patients with bilateral diffractive multifocal intraocular lenses (IOL) and patients with monofocal IOL monovision. METHODS Prospective nonrandomized controlled study. This study comprised consecutive bilateral cataract patients 45 cases (90eyes) between January 2011 and March 2012. All cases were divided into two groups: multifocal IOL group (23 patients) having implantation of AcrySof ReSTOR +3D(SN6AD1) multifocal IOL, monovision group (22 patients) having implantation of AcrySof IQ (SN60WF) IOL. Parameters analyzed 3 months postoperatively included binocular uncorrected distance, intermediate, and near visual acuities; stereo vision;photopic and mesopic contrast sensitivity function without glare. Parameters analyzed 6 months postoperatively included spectacle independence; subjective visual symptoms; and patient satisfaction. The independent-samples t test were used to compare the measure data which met normal distribution. The chi-square test was applied to compare categorical variables. RESULTS There were no significant differences between groups in bilateral uncorrected distance vision (0.13 ± 0.06, 0.17 ± 0.19; Z = 1.755, P = 0.086) , intermediate (0.34 ± 0.05,0.33 ± 0.06; Z = -0.821, P = 0.416) , and near vision (0.35 ± 0.06, 0.41 ± 0.09; Z = 2.117, P = 0.051) . There were significant differences between groups in stereo vision (Median: 150″, 525″; Z = -2.092, P = 0.036) . Percentage of patients wearing spectacle were less than 10% in all groups [91.3% (21/23), 90.9% (20/22) ].On the questionnaire, patients in multifocal IOL group complained with double vision, trouble in night vision and halo(21.7%). CONCLUSIONS Pseudophakic monovision and MIOL achieved distance vision, intermediate vision and near vision. But monovision was no risk for disturbing visual symptoms associated with multifocal IOL.